for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lexicon Pharmaceuticals, Inc.

LXRX.OQ

Latest Trade

4.07USD

Change

0.06(+1.50%)

Volume

245,150

Today's Range

3.90

 - 

4.15

52 Week Range

1.13

 - 

8.37

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.01
Open
4.00
Volume
245,150
3M AVG Volume
44.43
Today's High
4.15
Today's Low
3.90
52 Week High
8.37
52 Week Low
1.13
Shares Out (MIL)
106.27
Market Cap (MIL)
387.89
Forward P/E
-19.24
Dividend (Yield %)
--

Next Event

Q4 2019 Lexicon Pharmaceuticals Inc Earnings Release

Latest Developments

More

Lexicon Pharmaceuticals Inc Files For Mixed Shelf Of Upto $150 Million

Lexicon Pharmaceuticals Q3 Earnings Per Share $1.95

Lexicon Pharmaceuticals Reports Second Quarter 2019 Loss Per Share Of $0.22

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

Industry

Biotechnology & Drugs

Contact Info

8800 Technology Forest Pl

+1.281.8633000

http://www.lexpharma.com

Executive Leadership

Raymond Debbane

Independent Chairman of the Board

Lonnel Coats

President, Chief Executive Officer, Director

Jeffrey L. Wade

Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs

Pablo Lapuerta

Executive Vice President, Chief Medical Officer

Alan Main

Executive Vice President, Commercial Supply Operations

Key Stats

2.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.360

2017

-1.230

2018

-1.140

2019(E)

-0.190
Price To Earnings (TTM)
2.68
Price To Sales (TTM)
1.17
Price To Book (MRQ)
2.35
Price To Cash Flow (TTM)
2.30
Total Debt To Equity (MRQ)
148.82
LT Debt To Equity (MRQ)
141.97
Return on Investment (TTM)
51.45
Return on Equity (TTM)
43.73

Latest News

Latest News

Sanofi to pay Lexicon $260 million for terminated partnership

Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.

UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes.

Sanofi ends partnership with Lexicon to develop diabetes drug

French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

FDA advisory panel split over Sanofi-Lexicon diabetes drug

An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

FDA advisory panel split over Sanofi-Lexicon diabetes drug

Independent experts on an FDA advisory panel were equally split when voting on whether to approve an oral treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

BRIEF-Lexicon Pharmaceuticals Reports Q1 Loss Per Share $0.40

* LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BRIEF-‍Lexicon announces EMA acceptance of MAA for Sotagliflozin to treat adults with Type 1 Diabetes​

* LEXICON PHARMACEUTICALS ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES Source text for Eikon: Further company coverage:

BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes

* LEXICON PHARMACEUTICALS ANNOUNCES REGULATORY SUBMISSIONS FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES

BRIEF-Lexicon Pharmaceuticals Q4 Loss Per Share $0.27

* LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BRIEF-Biopharma Credit Says Enetered Into Term Loan Agreement For Up To US$200 Mln With Lexicon Pharmaceuticals

* BIOPHARMA CREDIT PLC SAYS ENETERED INTO A DEFINITIVE TERM LOAN AGREEMENT FOR UP TO US$200 MILLION WITH LEXICON PHARMACEUTICALS, INC. Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing

* LEXICON PHARMACEUTICALS SECURES UP TO $200 MILLION NON-DILUTIVE TERM LOAN FINANCING

BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.29

* Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update

BRIEF-Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211

* Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211 Source text for Eikon: Further company coverage:

BRIEF-Lexicon Pharmaceuticals gets European Commission's approval for Xermelo

* European Commission approves Xermelo (Telotristat Ethyl) for the treatment of Carcinoid Syndrome Diarrhea in combination with somatostatin analog therapy

BRIEF-Lexicon Pharma reports positive pooled continuous glucose monitoring data

* Lexicon Pharmaceuticals reports positive pooled continuous glucose monitoring data from pivotal phase 3 intandem1 and intandem2 studies of sotagliflozin

BRIEF-Lexicon Pharmaceuticals reports data from pivotal phase 3 intandem2 study of sotagliflozin

* Lexicon Pharmaceuticals reports additional positive data from pivotal phase 3 intandem2 study of sotagliflozin

BRIEF-Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes

* Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes

BRIEF-Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo

* Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo® (telotristat ethyl) Source text for Eikon: Further company coverage:

BRIEF-Lexicon Pharmaceuticals amends collaboration and license agreement

* Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up